Portfolio

Our Science in the Spotlight

Key publications

Human Respiratory Viruses
  • Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer. Bakkers et al. Nat. Comm. 2024 [Read more]
  • Structural basis for potent neutralization of human respirovirus type 3 by protective single-domain camelid antibodies. Johnson et al. Nat. Comm. 2024 [Read more]
  • Universal paramyxovirus vaccine design by stabilizing regions involved in structural transformation of the fusion protein. Langedijk et al. Nat. Comm. 2024 [Read more]
  • Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G. Voorzaat et al. Vaccines. 2024 [Read more]
  • Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity. Rutten et al. Sci Rep. 2024 [Read more]
  • Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen. Swart et al. NPJ Vaccines. 2023 [Read more]
  • Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike. Yu et al. PLoS Pathog. 2023 [Read more]
  • Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions. Milder et al. PNAS. 2022 [Read more]
  • Stabilizing the closed SARS-CoV-2 spike trimer. Juraszek et al. Nat. Comm. 2021 [Read more]
  • Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Mercado et al. Nature. 2020 [Read more]
  • Transient opening of trimeric prefusion RSV F proteins. Gilman et al. Nat. Comm. 2019 [Read more]
  • Betacoronavirus Adaptation to Humans Involved Progressive Loss of Hemagglutinin-Esterase Lectin Activity. Bakkers et al. Cell Host Microbe. 2017 [Read more]
  • Coronavirus receptor switch explained from the stereochemistry of protein-carbohydrate interactions and a single mutation. Bakkers et al. PNAS. 2016 [Read more]
  • A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Krarup et al. Nat. Comm. 2015 [Read more]
Emerging and neglected viruses
  • Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. Rutten et al. Cell Rep. 2020 [Read more]
  • CD164 is a host factor for lymphocytic choriomeningitis virus entry. Bakkers et al. PNAS. 2022 [Read more]
Human Immunodeficiency virus (HIV)
  • CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits. Koornneef et al. Nat. Commun. 2024 [Read more]
  • Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains. Rawi et al. Cell. Rep. 2020 [Read more]
  • A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. Rutten et. al. Cell Rep. 2018 [Read more]
  • HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. Eggink et al. J. Virol. 2016 [Read more]
  • A sweet surprise for HIV broadly neutralizing antibodies. Langedijk et al. Nature Medicine. 2012 [Read more]

Filed Patents

Vaccine design and others
  1. STABILIZED PRE-FUSION HMPV FUSION PROTEINS (WO2023110618A1)
  2. STABILIZED PRE-FUSION HMPV FUSION PROTEINS (WO2023217988A1)
  3. PRE-FUSION HUMAN PIV1 F PROTEINS (WO2024061757A1)
  4. STABILIZED PRE-FUSION PIV3 F PROTEINS (WO2024074584A1)
  5. RSV IMMUNOGENS (WO2024017682A1)
  6. STABILIZED PRE-FUSION RSV FB ANTIGENS (US-20240132548-A1)
  7. STABILIZED VACCINE COMPOSITIONS (US-20230310573-A1)
  8. RECOMBINANT INFLUENZA ANTIGENS (US-20220204567-A1)
  9. COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION – SARS-COV-2 VACCINES (US-20210388032-A1)
  10. RNA REPLICON ENCODING A STABILIZED CORONA VIRUS SPIKE PROTEIN (US-20210347828-A1)
  11. SARS-CoV-2 VACCINES (US-20210346492-A1)
  12. STABILIZED FILOVIRUS GLYCOPROTEIN TRIMERS (US-20210292371-A1)
  13. COMPOSITIONS AND VACCINE COMBINATIONS CONTAINING SYNTHETIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) ENVELOPE ANTIGEN, AND METHODS OF USE THEREOF (US-20210220468-A1)
  14. INFLUENZA VIRUS VACCINES AND USES THEREOF (US-20200377555-A1)
  15. POXVIRUS VECTORS ENCODING HIV ANTIGENS, AND METHODS OF USE THEREOF (US-20200138938-A1)
  16. VACCINE AGAINST RSV (US-20200061183-A1)
  17. VACCINE AGAINST RSV (US-20190125854-A1)
  18. STABILIZED SOLUBLE PRE-FUSION RSV F PROTEINS (US-20190119330-A1)
  19. TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS (US-20190023744-A1)
  20. STABILIZED VIRAL CLASS I FUSION PROTEINS (US-20180346521-A1)
  21. VACCINE AGAINST RSV (US-20180200360-A1)
  22. STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES (US-20180194808-A1)
  23. TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS (US-20180072777-A1)
  24. HUMAN IMMUNODEFICIENCY VIRUS ANTIGENS, VECTORS, COMPOSITIONS, AND METHODS OF USE THEREOF (US-20170165355-A1)
  25. STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES (US-20160176932-A1)
  26. HUMAN ANTIBODIES BINDING TO RSV G PROTEIN (US-20160145321-A1)
  27. HUMAN ANTIBODIES BINDING TO RSV G PROTEINS (US-20160145322-A1)
  28. STABILIZED SOLUBLE PREFUSION RSV F POLYPEPTIDES (US-20160102123-A1)

Let's Collaborate!

Your Project. Our Expertise